Sienna Biopharmaceuticals
Stage
Dead | DeadTotal Raised
$86MAbout Sienna Biopharmaceuticals
Sienna Biopharmaceuticals (NASDAQ: SNNA) is a medical dermatology and aesthetics company focused on developing safe and effective targeted therapies to treat inflammatory skin conditions and aesthetic concerns that impact the health and appearance of patients. Through its Topical by Design platform, Sienna is developing its lead assets, SNA-120 (TrkA inhibitor) for pruritus and psoriasis (Phase IIb) and SNA-125 (dual TrkA/JAK3 inhibitor) for atopic dermatitis, psoriasis, and pruritus (proof-of-concept). Through its photoparticle therapy platform, Sienna is developing SNA-001 for the treatment of acne vulgaris (pivotal trials) and for the permanent reduction of unwanted light-pigmented hair (pivotal trials).
Sienna Biopharmaceuticals Headquarter Location
30699 Russell Ranch Road Suite 140
Westlake Village, California, 91362,
United States
818-629-2256
Research containing Sienna Biopharmaceuticals
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Sienna Biopharmaceuticals in 1 CB Insights research brief, most recently on Apr 13, 2022.

Apr 13, 2022
406 startup failure post-mortemsExpert Collections containing Sienna Biopharmaceuticals
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Sienna Biopharmaceuticals is included in 1 Expert Collection, including Medical Devices.
Medical Devices
3,088 items
Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)
Sienna Biopharmaceuticals Patents
Sienna Biopharmaceuticals has filed 18 patents.
The 3 most popular patent topics include:
- Dosage forms
- Drug delivery devices
- Skin care
Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
12/9/2016 | 6/23/2020 | Nanomaterials, Polymers, Nanoparticles, Dosage forms, Nanotechnology | Grant |
Application Date | 12/9/2016 |
---|---|
Grant Date | 6/23/2020 |
Title | |
Related Topics | Nanomaterials, Polymers, Nanoparticles, Dosage forms, Nanotechnology |
Status | Grant |
Latest Sienna Biopharmaceuticals News
Nov 13, 2020
Nicole DeFeudis Associate Editor Frederick Beddingfield left Sienna Biopharmaceuticals last December, a few months after the struggling biotech filed for bankruptcy. The former CEO was planning to take some time off, until he received a call from the University of Pennsylvania professor Wenchao Song. Song was looking for someone to helm Kira Pharmaceuticals, a startup he co-founded to develop a “new generation” of complement-targeted therapies for immune-mediated diseases. The two got talking, one thing led to another, and “it just turned out to be a great fit,” Beddingfield said. On Thursday, Kira emerged from stealth mode with Beddingfield as CEO, $46 million from the venture well, and a lead candidate expected to hit the clinic in the next three months. “It’s the tip of the iceberg for complement diseases,” Beddingfield said. While the company is interested in improving on the standard of care for some diseases, “our bigger goal is to treat diseases where there’s really … a completely unmet need, and there are no complement drugs approved,” he said. The complement cascade, a part of the innate immune system, is “great when it’s working well,” Beddingfield said. But dysregulation can lead to autoimmune disorders. Depending on that dysregulation, blocking certain parts of the pathways that activate the complement system can be “quite effective” in controlling disease, the CEO said. “Sometimes patients have a genetic predisposition, some mutation in … part of this complement cascade that makes them have this abnormal response. Other times, we don’t know exactly why it’s exaggerated, but it is. And interestingly, if you look at Covid patients, many of them have (an) exaggerated complement cascade response,” he said. Kira’s lead candidate, P014, is designed to inhibit both upstream and downstream complement targets. It’s engineered with an extended half-life and potency, and has the potential to be self-administered at home. While Kira has yet to announce which indications it’s going after, Beddingfield said the candidate should enter the clinic within the next three months. The pipeline also includes two other candidates in IND-enabling stages. Cambridge, MA-based Kira was founded in 2017. While in stealth, it bagged an $18 million Series A and $28 million Series B from a slate of investors including Quan Capital, 6 Dimensions Capital, Qiming Venture Partners, and Sinopharm Capital. While its headquarters is in the US, the company also boasts a Suzhou, China office. “I think we’re the only complement company that from the get-go has a cross-border strategy to bring therapies … globally to the US to China,” Beddingfield said. This will allow the company to easily conduct clinical trials in both countries. Even so, the biotech may have some catching up to do. Alexion, which made waves with the introduction of its first anti-C5 antibody, snagged its second approval for the complement therapy Ultomiris last year. The drug, which blocks the C5 pathway, has the FDA’s OK to treat atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria. It raked in $338.9 million in net sales last year. Last August, Alexion was hit with a surprise inter partes review. The US Patent Trials Appeal Board action was stoked by Amgen, which pushed to overturn patents on the complement inhibitor Soliris to create a biosimilar. While Beddingfield once served as CMO of both Kythera and Allergan, his latest gig was at Sienna, which filed for a Chapter 11 last September. The biotech’s stock never quite recovered from the failure of its experimental acne drug SNA-001, which flopped in two separate trials testing its efficacy when managed by laser tech. The company cut 20 jobs in a restructuring to refocus on psoriasis and associated pruritus, and 7 more in connection with the bankruptcy filing. AUTHOR Jason Mast Associate Editor At 11 am after the election, Sherlock Biosciences CEO Rahul Dhanda snuck into his office and, in the couple minutes between meetings, fired off an email to his 45 employees. Dhanda had walked in calmly at 7 am, but over the next four hours, he watched his employees slumped at their desks. The entire office had sunk under a general malaise. He asked a team member why they were so distraught. They looked up and asked: “Why are you so calm?” Keep reading Endpoints with a free subscription Unlock this story instantly and join 93,900+ biopharma pros reading Endpoints daily — and it's free. SUBSCRIBE Less than four months after a $55 million raise, Seer is ready to go public. The company, run by Omid Farokhzad, filed for a $150 million IPO on Thursday as it prepares to jump onto the Nasdaq. Seer’s stock ticker will be fairly simple to remember — $SEER — and the move comes after the company has raised more than $150 million since being founded in 2017. Thursday’s news also comes less than a month after Seer’s main product, the Proteograph Product Suite, was delivered to one of its first collaborators, per the company’s S-1 . Funds from the IPO will go toward further commercializing the product and other R&D-related projects for Proteograph. Read More November 13, 2020 10:33 AM EST John Carroll Editor & Founder There will be no near-term OK for BioMarin’s hemophilia A gene therapy valrox in Europe. Already sent back by the FDA to gather more data on durability after researchers flagged a waning response over several years, the EMA had also pinned a request for extended results — though they were willing to take less than the US agency. On Friday, though, the EMA unveiled a November 4 letter from BioMarin $BMRN saying they were pulling their application — for now — because they wouldn’t have the added data within the time allowed for it. Keep reading Endpoints with a free subscription Unlock this story instantly and join 93,900+ biopharma pros reading Endpoints daily — and it's free. SUBSCRIBE John Carroll Editor & Founder Once the euphoria began to wane a bit following Pfizer’s dramatic unveiling of a 90%-plus effectiveness rate from its pivotal Covid-19 vaccine study earlier this week, less affluent countries and regions around the world began to wonder if they would ever be able to get in line for it. The vaccine has to be shipped in -70 degrees celsius temps and then used within 5 days of being thawed. For distributors in China, that means building a unique distribution system to deliver the first dose and then a booster. And there are plenty of countries that say they can’t afford to go that route — adding a big obstacle in front of a huge logistical challenge. Keep reading Endpoints with a free subscription Unlock this story instantly and join 93,900+ biopharma pros reading Endpoints daily — and it's free. SUBSCRIBE Assistant Editor → Co-founded by Nessan Bermingham and banking $91.5 million in Series A funding in September, RNA editing startup Korro Bio has tapped Ram Aiyar as their first CEO. Aiyar, who began as a research scientist in the immunology group at Janssen in the late 2000s, co-founded Corvidia Therapeutics in 2016 and was also their CFO and CBO along the way. Back in June, Aiyar helped steer the sale of Corvidia to Novo Nordisk for $2.1 billion, including $725 million upfront. With the deal , Novo Nordisk inserted Corvidia’s IL-6 inhibitor ziltivekimab into their pipeline. Keep reading Endpoints with a free subscription Unlock this story instantly and join 93,900+ biopharma pros reading Endpoints daily — and it's free. SUBSCRIBE
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.